• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Regulatory System Changes in Russia: A Historical Review and Future Perspectives.

作者信息

Lozda Raimond

机构信息

1 FMS Baltic Ltd, Regulatory Affairs Consultancy, Riga, Latvia.

出版信息

Ther Innov Regul Sci. 2016 Jul;50(4):414-418. doi: 10.1177/2168479015627853.

DOI:10.1177/2168479015627853
PMID:30227015
Abstract

The Russian pharmaceutical market is expected to grow and attract foreign investors. Nevertheless, the frequent changes in regulatory legislation make the process of marketing authorization in Russia much more challenging than in Europe. In the present review, an insight into the practical issues caused by the implementation of the new marketing authorization law from 2010 until now is provided. The outcome of the new law application is contrary to the old one from 1998, which was amended once in 2000. To date, it has already been revised 19 times. The reasons for the frequent amendments as well as future perspectives are provided.

摘要

相似文献

1
Regulatory System Changes in Russia: A Historical Review and Future Perspectives.
Ther Innov Regul Sci. 2016 Jul;50(4):414-418. doi: 10.1177/2168479015627853.
2
The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.
Ther Innov Regul Sci. 2017 Nov;51(6):751-755. doi: 10.1177/2168479017701978. Epub 2017 May 11.
3
Fighting trafficking of falsified and substandard medicinal products in Russia.打击俄罗斯假药和劣药的非法交易。
Int J Risk Saf Med. 2015;27 Suppl 1:S37-40. doi: 10.3233/JRS-150681.
4
[EU law on marketing authorization of medicines. History, current state of development and perspectives].[欧盟药品上市许可法律。历史、发展现状与前景]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Jul;51(7):705-12. doi: 10.1007/s00103-008-0576-8.
5
Pharmacovigilance in Russia: current state of affairs, challenges, and prospects.俄罗斯的药物警戒:现状、挑战与前景
Curr Med Res Opin. 2017 Dec;33(12):2161-2166. doi: 10.1080/03007995.2017.1336082. Epub 2017 Jun 25.
6
Almost 40 Years of Tissue Engineering in Russia: Where Are We Now?俄罗斯近40年的组织工程学发展:我们如今处于什么阶段?
Biomedicines. 2020 Feb 5;8(2):25. doi: 10.3390/biomedicines8020025.
7
Food legislation and its harmonization in Russia.俄罗斯的食品立法及其协调统一
J Sci Food Agric. 2014 Aug;94(10):1966-9. doi: 10.1002/jsfa.6197. Epub 2013 Jun 26.
8
[LEGAL BASIS FOR THE MOVEMENT OF MEDICINES ACROSS THE CUSTOMS BORDER OF THE EURASIAN ECONOMIC UNION BY LEGAL ENTITIES].
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2023 Oct;31(Special Issue 2):1248-1256. doi: 10.32687/0869-866X-2023-31-s2-1248-1256.
9
[Labor migration to Russia from nearby countries].
Vopr Ekon. 1996 Jan;1:85-94.
10
[Early achievements of the Danish pharmaceutical industry--8. Lundbeck].[丹麦制药行业的早期成就——8. 灵北公司]
Theriaca. 2016(43):9-61.

引用本文的文献

1
Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines.生物类似单克隆抗体开发的质量、非临床和临床考量:欧盟、世界卫生组织、美国、加拿大及金砖五国-巴西的监管指南
Front Pharmacol. 2018 Sep 28;9:1079. doi: 10.3389/fphar.2018.01079. eCollection 2018.